Mervin Smith Sells 1,352 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC) EVP Mervin Smith sold 1,352 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $128.44, for a total value of $173,650.88. Following the sale, the executive vice president owned 25,612 shares of the company’s stock, valued at approximately $3,289,605.28. This trade represents a 5.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mervin Smith also recently made the following trade(s):

• On Wednesday, February 25th, Mervin Smith sold 4,041 shares of iRhythm Technologies stock. The stock was sold at an average price of $135.42, for a total value of $547,232.22.
• On Tuesday, February 24th, Mervin Smith sold 732 shares of iRhythm Technologies stock. The shares were sold at an average price of $140.91, for a total transaction of $103,146.12.

iRhythm Technologies Price Performance

Shares of NASDAQ:IRTC opened at $127.95 on Thursday. The firm’s 50 day moving average price is $158.44 and its 200-day moving average price is $169.85. The company has a quick ratio of 4.48, a current ratio of 4.63 and a debt-to-equity ratio of 4.25. The stock has a market capitalization of $4.14 billion, a PE ratio of -91.39 and a beta of 1.09. iRhythm Technologies has a twelve month low of $92.52 and a twelve month high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings results on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.27. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The business had revenue of $208.89 million for the quarter, compared to the consensus estimate of $202.61 million. During the same period last year, the firm earned ($0.04) earnings per share. The company’s quarterly revenue was up 27.1% on a year-over-year basis. Equities research analysts expect that iRhythm Technologies will post -1.98 EPS for the current year.

Hedge Funds Weigh In On iRhythm Technologies

Several hedge funds have recently modified their holdings of the stock. MidFirst Bank bought a new position in shares of iRhythm Technologies during the fourth quarter worth $235,000. Corient Private Wealth LLC lifted its stake in iRhythm Technologies by 12.1% in the 4th quarter. Corient Private Wealth LLC now owns 1,764 shares of the company’s stock worth $313,000 after purchasing an additional 191 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in iRhythm Technologies by 7.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 639,423 shares of the company’s stock worth $113,459,000 after purchasing an additional 44,175 shares in the last quarter. XTX Topco Ltd bought a new position in shares of iRhythm Technologies during the 4th quarter valued at about $855,000. Finally, RTW Investments LP purchased a new position in shares of iRhythm Technologies during the fourth quarter valued at about $209,732,000.

Trending Headlines about iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $870.0M–$880.0M versus consensus near $817M, signaling stronger demand and faster revenue growth than expected; the company also reported a solid February quarter beat (revenue +27% YoY and EPS above estimates), supporting the outlook.
• Neutral Sentiment: Analysts are recalibrating assumptions: several firms trimmed price targets while mostly keeping Buy/Overweight ratings — that creates mixed analyst signals as models are adjusted around the new guidance and profitability timing. Analyst coverage note
• Negative Sentiment: Clustered insider selling on March 2: multiple senior executives (CAO and several EVPs) sold shares — collectively roughly 17.8k shares for ≈$2.3M at ~ $128.44 per share — a mid‑single‑digit reduction in each holder’s stake. While insiders still retain material positions, the concentrated timing of the sales is likely weighing on near‑term sentiment. Insider trades alert

Wall Street Analysts Forecast Growth

IRTC has been the subject of a number of analyst reports. Morgan Stanley restated an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. Canaccord Genuity Group reduced their target price on shares of iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a report on Friday, February 20th. Robert W. Baird lowered their price target on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating on the stock in a report on Friday, February 20th. Freedom Capital upgraded shares of iRhythm Technologies to a “strong-buy” rating in a research report on Thursday, January 15th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating on the stock in a research report on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, iRhythm Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $211.62.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.